Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

The periodontal pathogen Porphyromonas gingivalis induces the Epstein-Barr virus lytic switch transactivator ZEBRA by histone modification.

Imai K, Inoue H, Tamura M, Cueno ME, Inoue H, Takeichi O, Kusama K, Saito I, Ochiai K.

Biochimie. 2012 Mar;94(3):839-46. doi: 10.1016/j.biochi.2011.12.001. Epub 2011 Dec 8.

PMID:
22178321
2.

Reactivation of latent HIV-1 infection by the periodontopathic bacterium Porphyromonas gingivalis involves histone modification.

Imai K, Ochiai K, Okamoto T.

J Immunol. 2009 Mar 15;182(6):3688-95. doi: 10.4049/jimmunol.0802906.

3.

Role of the histone H3 lysine 9 methyltransferase Suv39 h1 in maintaining Epsteinn-Barr virus latency in B95-8 cells.

Imai K, Kamio N, Cueno ME, Saito Y, Inoue H, Saito I, Ochiai K.

FEBS J. 2014 May;281(9):2148-58. doi: 10.1111/febs.12768. Epub 2014 Mar 17.

5.

Histone acetylation and reactivation of Epstein-Barr virus from latency.

Jenkins PJ, Binné UK, Farrell PJ.

J Virol. 2000 Jan;74(2):710-20.

6.
7.
8.

Transcriptional repression by sumoylation of Epstein-Barr virus BZLF1 protein correlates with association of histone deacetylase.

Murata T, Hotta N, Toyama S, Nakayama S, Chiba S, Isomura H, Ohshima T, Kanda T, Tsurumi T.

J Biol Chem. 2010 Jul 30;285(31):23925-35. doi: 10.1074/jbc.M109.095356. Epub 2010 Jun 1.

9.

Induction of Epstein-Barr virus (EBV) reactivation in Raji cells by doxorubicin and cisplatin.

Hsu CH, Hergenhahn M, Chuang SE, Yeh PY, Wu TC, Gao M, Cheng AL.

Anticancer Res. 2002 Nov-Dec;22(6C):4065-71.

PMID:
12553034
10.

Relationship between Porphyromonas gingivalis, Epstein-Barr virus infection and reactivation in periodontitis.

Sugano N, Ikeda K, Oshikawa M, Idesawa M, Tanaka H, Sato S, Ito K.

J Oral Sci. 2004 Dec;46(4):203-6.

11.
12.

Epstein-Barr virus lytic transactivator Zta enhances chemotactic activity through induction of interleukin-8 in nasopharyngeal carcinoma cells.

Hsu M, Wu SY, Chang SS, Su IJ, Tsai CH, Lai SJ, Shiau AL, Takada K, Chang Y.

J Virol. 2008 Apr;82(7):3679-88. doi: 10.1128/JVI.02301-07. Epub 2008 Jan 30.

13.

Switching of EBV cycles between latent and lytic states.

Murata T, Tsurumi T.

Rev Med Virol. 2014 May;24(3):142-53. doi: 10.1002/rmv.1780. Epub 2013 Dec 11. Review.

PMID:
24339346
14.
15.

The chemopreventive compound curcumin is an efficient inhibitor of Epstein-Barr virus BZLF1 transcription in Raji DR-LUC cells.

Hergenhahn M, Soto U, Weninger A, Polack A, Hsu CH, Cheng AL, Rösl F.

Mol Carcinog. 2002 Mar;33(3):137-45.

PMID:
11870879
17.

A molecular link between malaria and Epstein-Barr virus reactivation.

Chêne A, Donati D, Guerreiro-Cacais AO, Levitsky V, Chen Q, Falk KI, Orem J, Kironde F, Wahlgren M, Bejarano MT.

PLoS Pathog. 2007 Jun;3(6):e80.

18.
19.

Functional and physical interactions between the Epstein-Barr virus (EBV) proteins BZLF1 and BMRF1: Effects on EBV transcription and lytic replication.

Zhang Q, Hong Y, Dorsky D, Holley-Guthrie E, Zalani S, Elshiekh NA, Kiehl A, Le T, Kenney S.

J Virol. 1996 Aug;70(8):5131-42.

20.

Nuclear factor-Y and Epstein Barr virus in nasopharyngeal cancer.

Chia MC, Leung A, Krushel T, Alajez NM, Lo KW, Busson P, Klamut HJ, Bastianutto C, Liu FF.

Clin Cancer Res. 2008 Feb 15;14(4):984-94. doi: 10.1158/1078-0432.CCR-07-0828.

Supplemental Content

Support Center